# Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer

> **NCT04510584** · PHASE2 · WITHDRAWN · sponsor: **University Health Network, Toronto**

## Conditions studied

- Ovarian Endometrioid Tumor
- Fallopian Tube Cancer
- Primary Peritoneal Cancer
- TP53 Mutation

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT04510584
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-07-16
- **Primary completion:** 2023-02-22
- **Final completion:** 2023-02-22
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** 19 patients screenfailed, stopping recruitment before first patient enrollment to analyze pilot results from screening samples.
- **Last updated:** 2023-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04510584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04510584, "Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04510584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*